Postprogression outcomes in patients with ovarian carcinoma associated with a mutation in a non-BRCA homologous recombination repair gene receiving rucaparib maintenance treatment: Results from the phase III study ARIEL3
Year: 2020
Type: article
Source: Gynecologic Oncology
Authors: D.M. O'Malley, A.M. Oza, D. Lorusso, C. Aghajanian, A. Oaknin, A. Dean, N. Colombo, J.I. Weberpals, A.R. Clamp, G. Scambia, A. Leary, R.W. Holloway, M. Amenedo Gancedo, P.C. Fong, J.C. Goh, D.K. Armstrong, S. Banerjee, J. García-Donas, E.M. Swisher, T. Cameron, L. Maloney, S. Goble, K.K. Lin, J.A. Ledermann, R.L. Coleman
Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, University Health Network, Princess Margaret Cancer Centre, Agostino Gemelli University Polyclinic, Memorial Sloan Kettering Cancer Center, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, St John of God Subiaco Hospital, European Institute of Oncology, Ottawa Hospital Research Institute, University of Manchester, The Christie NHS Foundation Trust, Inserm, Institut Gustave Roussy, Florida Hospital Cancer Institute, Centro Oncológico de Galicia, Auckland City Hospital, The University of Queensland, Royal Brisbane and Women's Hospital, Johns Hopkins University, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, HM Hospitales, University of Washington, Clovis Oncology (United Kingdom), Clovis Oncology (United States), University College London, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3015766445